Clinical Trials · NCT02021942

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Name: Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Octreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Prof. Dr. Berthold Schalke
Enrollment: 16
Start date: Mar 2012
Locations: 1 site, Germany
Primary endpoint: Percent Change in Tumor Volume From Baseline to EOS

View Octreotide compound reference